DoD Melanoma, Translational Research Award by Department of Defense
The Department of Defense offers the FY19 MRP Translational Research Award to support hypothesis-driven, translational research with a focus on critical scientific or clinical melanoma issues. The award encourages mature research projects that can make a significant impact through identifying scientific outcomes translatable to treatment and prevention strategies. The research should accelerate promising findings, advance the understanding of melanoma, and leverage clinical samples to maximize impact. Applications should not focus on late-stage disease models, PD-1 combinations, or non-melanoma skin cancers, aiming for high-impact, translatable results. Deadline for submissions is Oct 23, 2019.
Science and Technology and other Research and Development
Category Explanation:
–
Expected Number of Awards:
2
Assistance Listings:
12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Version:
Synopsis 1
Posted Date:
May 16, 2019
Last Updated Date:
May 16, 2019
Original Closing Date for Applications:
Oct 23, 2019
Current Closing Date for Applications:
Oct 23, 2019
Archive Date:
Nov 22, 2019
Estimated Total Program Funding:
$1,920,000
Award Ceiling:
–
Award Floor:
–
Eligibility
Eligible Applicants:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
–
Additional Information
Agency Name:
Dept. of the Army — USAMRAA
Description:
The FY19 MRP Translational Research Award supports
hypothesis-driven, translational, high-impact research. The
Translational Research Award mechanism encourages applications with mature
research projects that specifically focus on critical scientific or clinical
melanoma issues, which, if successfully addressed, have the potential to make a
major impact. Important factors under consideration will be continuity of
research, clinical applicability, and leveraging of clinical samples from
clinical trials and/or biorepositories. The Translational Research Award
supports identifying scientific outcomes, through rigorous, robust research,
that are translatable toward treatment and/or preventive strategies. Research
proposed should aim to accelerate promising findings toward clinical
applicability and leverage research results to maximize impact. Proposed
studies should focus on the commonalities in melanoma research to advance the
understanding of the field The Translational Research Award is not intended
to study research into established late-stage disease models, clinical utility
of PD-1 in combination with other therapeutics, or established cell lines.
The MRP is not requesting research into established
macrometastatic disease, models of metastatic disease using established cell
lines, or treatment of macrometastatic disease. Studies involving non-melanoma
skin cancers are not allowed under the FY19 MRP.
Link to Additional Information:
–
Grantor Contact Information:
If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org Email:help@eBRAP.org
Version History
Version
Modification Description
Updated Date
Related Documents
Folder 316057 Full Announcement-FY19 MRP TRA -> MRP_FY19_TRA_GG-dmk.pdf
Packages
Agency Contact Information:
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org
